RNXT (RenovoRx, Inc.) מחיר לרווח עתידי

לוגו גרפי של RenovoRx, Inc. (RNXT)

RenovoRx, Inc. (RNXT) develops automated RenovoCath systems for the precise delivery of chemotherapy into gastrointestinal tumors, aiming to establish technological leadership in targeted therapy. The company's forward P/E metric on the GURU.Markets platform chart reflects market confidence, where the value of 0.00 corresponds to the current metric. However, certification challenges for hybrid products could significantly delay the business's path to break-even.

RenovoRx - יחס שווי שוק לרווח עתידי RNXT (תקופה 04.07.2022 - 16.11.2026)

פילוחי מדדים ואנליטיקה של חברת RenovoRx, Inc. (RNXT)

- מחיר נוכחי ושווי מניות חזוי:
- מדדי הערכת שווי שוק של העסק:
ניתוח מקיף של החברה:RenovoRx Corporation
מוצר ממותג של RenovoRx Corporation

This indicator compares current market value with projected earnings, identifying trend reversal points through intraday calculations of investor expectations and correction risks. By analyzing the business's forward P/E, one can assess the premium the market is pricing in for the success of the RenovoRx, Inc. (RNXT) RenovoCath system and the company's patents, which create a defensive barrier in the pancreatic tumor targeted therapy niche.